Amarin Corp Plcuk (AMRN) Operating Margin (2013 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Operating Margin of 25.11% for Q1 2026, up 1476.0% YoY from 1.59% in Q1 2025, and down 135.48% sequentially from 70.77% in Q4 2025.
Amarin Corp Plcuk (AMRN) Operating Margin (2013 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Operating Margin across 14 years of filings, most recently posting 25.11% for Q1 2026.
- In Q1 2026, Operating Margin rose 1476.0% year-over-year to 25.11%; the TTM figure through Mar 2026 stood at 1.66% (up 884.0% YoY), while the FY2025 annual figure was 4.22%, up 422.0% from the prior year.
- Operating Margin declined to 25.11% in Q1 2026, from 70.77% in the prior quarter.
- Over the last five years, Operating Margin for AMRN reached as high as 70.77% in Q4 2025 and fell as low as 66.53% in Q2 2022.
- The 5-year median for Operating Margin is 22.35% (2025), against an average of 12.95%.
- Annual changes were most pronounced in 2022 — Operating Margin sank 7221 bps — and 2023, when it jumped 7665 bps.
- A 5-year view of Operating Margin shows it stood at 10.62% in 2022, then surged by 722 bps to 66.03% in 2023, then slumped by 51 bps to 32.06% in 2024, then jumped by 121 bps to 70.77% in 2025, then tumbled by 135 bps to 25.11% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 25.11%, 70.77%, and 22.35% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 47.98% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 26.44% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 26.60% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 29.51% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -286.83% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | -25.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.11% |
| Dec 31, 2025 | 70.77% |
| Sep 30, 2025 | -22.35% |
| Jun 30, 2025 | -21.98% |
| Mar 31, 2025 | -39.88% |
| Dec 31, 2024 | 32.06% |
| Sep 30, 2024 | -59.50% |
| Jun 30, 2024 | -0.78% |
| Mar 31, 2024 | -24.03% |
| Dec 31, 2023 | 66.03% |
| Sep 30, 2023 | -32.47% |
| Jun 30, 2023 | -29.89% |
| Mar 31, 2023 | -20.17% |
| Dec 31, 2022 | -10.62% |
| Sep 30, 2022 | -5.72% |
| Jun 30, 2022 | -66.53% |
| Mar 31, 2022 | -29.91% |
| Dec 31, 2021 | 5.85% |
| Sep 30, 2021 | -9.20% |
| Jun 30, 2021 | 5.68% |